Form 4: Amgen EVP James Bradner Disposes Shares for Tax Obligations

Amgen Inc. EVP of Research and Development James E. Bradner disposed of 446 shares of common stock to satisfy tax withholding obligations.

Summary

• James E. Bradner, EVP of Research and Development at Amgen Inc., sold 446 shares of common stock.
• The transaction occurred on May 7, 2026, at a price of $331.11 per share.
• The disposal was executed to satisfy tax withholding obligations related to the vesting of equity awards.
• Following this transaction, the reporting person maintains beneficial ownership of 30,016 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the share disposal was purely for tax compliance purposes and does not reflect a change in the executive's outlook on the company.

Positives

• The transaction was a routine administrative action related to tax withholding rather than a discretionary market sale.

Negatives

• Reduction in the direct equity stake held by a key executive.

Risks

• None identified; this is a standard regulatory filing for executive compensation tax compliance.

Future Outlook

Not applicable; this is a retrospective disclosure of an insider transaction.

Industry Context

StockSavvy.ai notes that routine Form 4 filings for tax withholding are standard practice in the biotechnology sector and do not typically signal changes in executive sentiment regarding company performance.

Comparison to Industry Standards

• The transaction aligns with standard executive compensation practices at large-cap pharmaceutical companies where equity vesting triggers mandatory tax withholding.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a non-discretionary tax-related event.

Key Dates

Keywords

Amgen, AMGN, Form 4, Insider Trading, Executive Compensation, Biotechnology